Available liver cancer risk prediction models have primarily focused on high-risk populations, such as the THRI (Toronto HCC Risk Index) [5] and GES (General Evaluation Score) [6] for patients with cirrhosis and the REACH-B (Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B) [7], PAGE-B (Platelets, Age, Gender, and HBV) [8], AGED (Age, Gender, HBV e antigen, and HBV DNA) [9], and aMAP (Age, Male, Albumin-bilirubin, and Platelets) [14] for individuals with HBV infection, HCV infection, and chronic hepatitis with different etiologies. This evidence concerns the gene ALB and chronic hepatitis.